Lysosomal storage disorder biotech Gain Therapeutics files for a $40 million IPO

Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offering.

Gain Therapeutics is developing novel therapies to treat diseases caused by pRead More